1. Home
  2. ARIS vs URGN Comparison

ARIS vs URGN Comparison

Compare ARIS & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARIS
  • URGN
  • Stock Information
  • Founded
  • ARIS 2015
  • URGN 2004
  • Country
  • ARIS United States
  • URGN United States
  • Employees
  • ARIS N/A
  • URGN N/A
  • Industry
  • ARIS Water Supply
  • URGN Biotechnology: Pharmaceutical Preparations
  • Sector
  • ARIS Utilities
  • URGN Health Care
  • Exchange
  • ARIS Nasdaq
  • URGN Nasdaq
  • Market Cap
  • ARIS 698.2M
  • URGN 831.6M
  • IPO Year
  • ARIS 2021
  • URGN 2017
  • Fundamental
  • Price
  • ARIS $21.28
  • URGN $19.31
  • Analyst Decision
  • ARIS Buy
  • URGN Strong Buy
  • Analyst Count
  • ARIS 7
  • URGN 8
  • Target Price
  • ARIS $25.86
  • URGN $29.00
  • AVG Volume (30 Days)
  • ARIS 632.6K
  • URGN 1.3M
  • Earning Date
  • ARIS 08-11-2025
  • URGN 08-07-2025
  • Dividend Yield
  • ARIS 2.64%
  • URGN N/A
  • EPS Growth
  • ARIS 16.74
  • URGN N/A
  • EPS
  • ARIS 0.83
  • URGN N/A
  • Revenue
  • ARIS $452,529,000.00
  • URGN $91,871,000.00
  • Revenue This Year
  • ARIS $13.43
  • URGN $39.80
  • Revenue Next Year
  • ARIS $3.71
  • URGN $108.94
  • P/E Ratio
  • ARIS $25.59
  • URGN N/A
  • Revenue Growth
  • ARIS 12.03
  • URGN 8.98
  • 52 Week Low
  • ARIS $13.34
  • URGN $3.42
  • 52 Week High
  • ARIS $33.95
  • URGN $19.69
  • Technical
  • Relative Strength Index (RSI)
  • ARIS 38.53
  • URGN 76.58
  • Support Level
  • ARIS $20.55
  • URGN $18.37
  • Resistance Level
  • ARIS $21.53
  • URGN $19.74
  • Average True Range (ATR)
  • ARIS 0.71
  • URGN 1.01
  • MACD
  • ARIS -0.03
  • URGN 0.21
  • Stochastic Oscillator
  • ARIS 27.65
  • URGN 92.77

About ARIS Aris Water Solutions Inc.

Aris Water Solutions Inc is an environmental infrastructure and solutions company delivering full-cycle water handling and recycling solutions. Its integrated pipelines and related infrastructure create long-term value by delivering high-capacity, comprehensive produced water management, recycling, and supply solutions to operators in the core areas of the Permian Basin. The company manages its business through a single operating segment comprising two primary revenue streams, Produced Water Handling and Water Solutions. The Produced Water Handling business gathers, transports, and unless recycled, handles produced water generated from oil and natural gas production, and the Water Solutions business develops and operates recycling facilities to treat, store, and recycle produced water.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

Share on Social Networks: